ReviewJournal of neuro-oncology2020
Molecular markers and targeted therapy in pediatric low-grade glioma.
Review in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Precision oncology in a dish: patient-derived glioma organoids to guide novel therapeutic strategies.Biomarker research · 2026Article
- Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.Acta neuropathologica communications · 2025Review
- Significance of miR-1290 in glioblastoma patients with epilepsy.Scientific reports · 2025Article
- Carboplatin desensitization in the era of target therapies: still worthwhile?Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Article
- Phenotypic and epigenetic heterogeneity in FGFR2-fused glial and glioneuronal tumours.Neuropathology and applied neurobiology · 2024Article
- Intramedullary pediatric low-grade glioma of the spine.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Review
- Novel insights on genetics and epigenetics as clinical targets for paediatric astrocytoma.Clinical and translational medicine · 2024Review
- Identification and validation of a novel Parkinson-Glioma feature gene signature in glioma and Parkinson's disease.Frontiers in aging neuroscience · 2024Article
- Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.Frontiers in immunology · 2024Article
- Low-Grade Gliomas: Histological Subtypes, Molecular Mechanisms, and Treatment Strategies.Brain sciences · 2023Review
- Evolving Diagnostic and Treatment Strategies for Pediatric CNS Tumors: The Impact of Lipid Metabolism.Biomedicines · 2023Review
- Molecular Heterogeneity in BRAF-Mutant Gliomas: Diagnostic, Prognostic, and Therapeutic Implications.Cancers · 2023Review
- Pediatric low-grade glioma models: advances and ongoing challenges.Frontiers in oncology · 2023Review
- DNALI1 is a prognosis-related biomarker and correlates with immune infiltrates in low grade glioma.Cancer biomarkers : section A of Disease markers · 2023Article
- Medical Treatment of Pediatric Low-Grade Glioma.Brain tumor research and treatment · 2022Review
- Emerging glioneuronal and neuronal tumors: case-based review.Brain tumor pathology · 2022Review
- Integrative analysis reveals the functional implications and clinical relevance of pyroptosis in low-grade glioma.Scientific reports · 2022Article
- Glioma targeted therapy: insight into future of molecular approaches.Molecular cancer · 2022Review
- Article
- Transcriptome Analysis and Single-Cell Sequencing Analysis Constructed the Ubiquitination-Related Signature in Glioma and Identified USP4 as a Novel Biomarker.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecently discovered molecular alterations in pediatric low-grade glioma have helped to refine the classification of these tumors and offered novel targets for therapy. Genetic aberrations may combine with histopathology to offer new insights into glioma classification, gliomagenesis and prognosis. Therapies targeting common genetic aberrations in the MAPK pathway offer a novel mechanism of tumor control that is currently under study.
methodsWe have reviewed common molecular alterations found in pediatric low-grade glioma as well as recent clinical trials of MEK and BRAF inhibitors.
resultsIn this topic review, we examine the current understanding of molecular alterations in pediatric low-grade glioma, as well as their role in diagnosis, prognosis and therapy. We summarize current data on the efficacy of targeted therapies in pediatric low-grade gliomas, as well as the many unanswered questions that these new discoveries and therapies raise.
conclusionsThe identification of driver alterations in pediatric low-grade glioma and the development of targeted therapies have opened new therapeutic avenues for patients with low-grade gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.